Cargando…

Disrupting ATF4 Expression Mechanisms Provides an Effective Strategy for BRAF-Targeted Melanoma Therapy

BRAF V600 mutation influences cellular signaling pathways for melanoma development. However, the role of oncogenic BRAF in adaptive stress response pathways is not fully understood. Here, we show that oncogenic BRAF plays an essential role in the induction of ATF4 following the activation of general...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagasawa, Ikuko, Koido, Masaru, Tani, Yuri, Tsukahara, Satomi, Kunimasa, Kazuhiro, Tomida, Akihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155235/ https://www.ncbi.nlm.nih.gov/pubmed/32283529 http://dx.doi.org/10.1016/j.isci.2020.101028

Ejemplares similares

Spautin-1 inhibits mitochondrial complex I and leads to suppression of the unfolded protein response and cell survival during glucose starvation
por: Kunimasa, Kazuhiro, et al.
Publicado: (2022)

InDePTH: detection of hub genes for developing gene expression networks under anticancer drug treatment
por: Koido, Masaru, et al.
Publicado: (2018)

Mitochondrial deficiency impairs hypoxic induction of HIF-1 transcriptional activity and retards tumor growth
por: Koido, Masaru, et al.
Publicado: (2017)

Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation
por: Mashima, Tetsuo, et al.
Publicado: (2015)

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies
por: Zhong, Jingqin, et al.
Publicado: (2022)

Mitochondrial ATF2 translocation contributes to apoptosis induction and BRAF inhibitor resistance in melanoma through the interaction of Bim with VDAC1
por: Gao, Zongwei, et al.
Publicado: (2015)

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
por: Spagnolo, Francesco, et al.
Publicado: (2015)

BRAF and beyond: Tailoring strategies for the individual melanoma patient
por: Jarkowski, Anthony, et al.
Publicado: (2014)

TBL2 Is a Novel PERK-Binding Protein that Modulates Stress-Signaling and Cell Survival during Endoplasmic Reticulum Stress
por: Tsukumo, Yoshinori, et al.
Publicado: (2014)

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
por: Curl, Patti, et al.
Publicado: (2014)

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
por: Curl, Patti, et al.
Publicado: (2015)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Targeting BRAF for patients with melanoma
por: Arkenau, H-T, et al.
Publicado: (2011)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma
por: Saei, Azad, et al.
Publicado: (2019)

A Role for ATF2 in Regulating MITF and Melanoma Development
por: Shah, Meera, et al.
Publicado: (2010)

Optimizing the treatment of BRAF mutant melanoma
por: Settleman, Jeff
Publicado: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
por: Kainthla, Radhika, et al.
Publicado: (2013)

The immune‐related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2014)

The immune-related role of BRAF in melanoma
por: Tomei, Sara, et al.
Publicado: (2015)

BRAF Gene and Melanoma: Back to the Future
por: Ottaviano, Margaret, et al.
Publicado: (2021)

BRAF Mutation Heterogeneity in Melanoma Lesions
por: SAKAIZAWA, Kaori, et al.
Publicado: (2020)

Proteasome dysfunction disrupts adipogenesis and induces inflammation via ATF3
por: Willemsen, Nienke, et al.
Publicado: (2022)

Efficient prediction of a spatial transcriptomics profile better characterizes breast cancer tissue sections without costly experimentation
por: Monjo, Taku, et al.
Publicado: (2022)

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma()()
por: Kim, Hee Kyung, et al.
Publicado: (2016)

Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
por: Dolinsek, Tanja, et al.
Publicado: (2016)

Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours
por: Tate, Sonya C, et al.
Publicado: (2016)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

Dependence On Glycolysis Sensitizes BRAF-mutated Melanomas For Increased Response To Targeted BRAF Inhibition
por: Hardeman, Keisha N., et al.
Publicado: (2017)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Clinical significance of BRAF mutations in metastatic melanoma
por: Chang, David Z, et al.
Publicado: (2004)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
por: Sullivan, Ryan J., et al.
Publicado: (2011)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

Beyond BRAF: where next for melanoma therapy?
por: Fedorenko, I V, et al.
Publicado: (2015)

Variations of BRAF mutant allele percentage in melanomas
por: Hélias-Rodzewicz, Zofia, et al.
Publicado: (2015)

Novel combination therapies for BRAF-mutant melanoma
por: McArthur, Grant A
Publicado: (2015)

Development of encorafenib for BRAF-mutated advanced melanoma
por: Koelblinger, Peter, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ok2dbqkq6em8lh4uf7vc3151tu